Active Studies
Today, there are numerous ongoing research efforts aiming to help T1D patients and their families. We are here to help these scientists and medical professionals help us.
An international study is designed to test two different body-acceptance programs for female T1D patients between the ages of 14-35, aiming to improve body acceptance and eating habits.
Researchers at Vanderbilt University are conducting a study on digital storytelling for teens with Type 1 Diabetes. The study will explore how creating personal stories about living with diabetes can help with managing stress, feeling supported, and improving self-care.
A research study that aims to evaluate the safety and effectiveness of an inhaled insulin product for youth aged 4-17 with type 1 or type 2 diabetes.
A study at Stanford University is investigating risk factors that predict future onset of eating disorders in T1D female adolescents between the ages of 11-17 who use a CGM.
This study explores how artificial intelligence (AI) can help doctors choose insulin pump settings in a system that uses automated insulin delivery for T1D patients between 2-5 years old.
A study for teenagers between the ages of 11-17 who have had T1D for at least 6 months, with the goal of improving bolusing in teenagers.
Medtronic is looking for study participants aged 2-6 years with type 1 diabetes to evaluate the safety of the MiniMed 780G insulin pump with the DS5 CGM.
Stanford University has a research study on the use of diabetes technologies in the hospital for people who had a hospital stay within the past year.
TrialNet researchers are testing two different treatments – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people (aged 12-35) newly diagnosed with type 1 diabetes (Stage 3 T1D).
This study tests a low dose of the immunotherapy drug anti-thymocyte globulin (ATG) to see if it can delay or prevent T1D in people aged 12 to 34 who have a 50% risk of clinical diagnosis within 2 years.
Teens (aged 14-17) are needed to help preteens with type 1 diabetes stay positive and motivated to manage their condition.
Youth from marginalized and underrepresented backgrounds are at a systematic disadvantage in the provision of diabetes care. This study aims to address the gap in knowledge, and identify and address factors of worsening disparity in diabetes technology.
A study for T1D patients between the ages of 12-29 who were diagnosed within the last 6 months, testing a treatment to see if it is able to preserve the body's insulin-producing capacity.
A study on a drug known as difluoromethylornithine (DFMO) that may reduce stress in cells that make insulin and preserve the body’s insulin production for T1D patients diagnosed within the past 100 days
This study is testing rituximab-pvvr and abatacept in people (aged 8-45) who were newly diagnosed with type 1 diabetes (T1D) to learn if using both immune therapies, one after the other, maintains the body’s ability to make insulin.
Archived
List of studies that are not active or not recruiting any more.
Teplizumab (TZield) is a humanized antibody to delay the onset of stage 3 type 1 diabetes in people with stage 2 T1D. This clinical trial is for children less than 8 years old in stage 2 T1D.
A 22-week clinical trial aiming to determine the safety and effectiveness of Dapagliflozin, which manages glucose and improves kidney function in teens aged 12 to 18 with T1D.
A study to evaluate whether ladarixin is effective in preserving beta cell function and slowing down the progression of T1D for patients between 14 and 45 years old who are diagnosed within 100 days of first insulin administration.
A survey for parents/caregivers of children and youth living with T1D aiming to understand their perspectives regarding the use of new disease-modifying drugs.